Sterilization products maker STERIS (NYSE:STE) reported that shipments of its System 1E sterilizer continue to fall below the company’s earlier projections. The System 1E is a liquid chemical ...

Sterilization products maker STERIS (NYSE:STE) is experiencing a more slow and costly transition to a new version of its flagship sterilization system than the company expected. The company had ...

Federal regulators have given Steris Corp. permission to start selling an accessory for its flagship product, but the approval would have had a bigger impact had it come sooner, according to a Steris ...

STERIS Corp. has received FDA’s 510(k) clearance for software modifications to its System 1E liquid chemical sterilant processing system, according to a FDA report and a MEDCity report.

MENTOR, Ohio--(BUSINESS WIRE)-- STERIS Corporation (NYSE: STE) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the STERIS SYSTEM 1E ® Liquid Chemical ...

Steris Corp. chief executive Walt Rosebrough on Tuesday announced the company's plans to build an $11 million facility in Mentor and add 300 jobs there over the next three years. The positions include ...

The U.S. Food and Drug Administration has prohibited further distribution of a STERIS Corp. liquid chemical sterilization system, but its customers will have some recourse. As part of the consent ...

Despite a few hurdles — a big drop in shipments, regulatory issues and a big-name competitor — Steris Corp. says it could sell as many as 9,300 System 1E machines while hospitals still are scrambling ...

MENTOR, Ohio--STERIS Corp., a Mentor-based healthcare technology company, plans to close one of its local plants next year, eliminating about 100 jobs. A restructuring plan sparked by soft demand for ...

The hit STERIS took when it assessed its fiscal year 2011 first-quarter performance was both expected and planned for. As Tuesday’s results show, it was also slightly offset. The infection prevention ...

Steris (STE) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most ...